Clinical Trial: Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Intraocular Inflammation
Study Type: OBSERVATIONAL
Official Title: Real-life Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy
Brief Summary:
Faricimab (Vabysmo®), a novel pharmaceutical agent is a promising treatment for age-related macular degeneration and diabetic macular edema due to its dual mechanism of action, targeting both the VEGF and angiopoietin-2 (Ang-2) pathways, offering potential benefits in improving visual outcomes and reducing treatment burdens.The phase 3 TENAYA and LUCERNE clinical trials have demonstrated its efficacy and safety profile, leading to regulatory approval and increasing use in clinical practice.However, as with any new…
Read more